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Abstract
Anaplastic carcinoma of the thyroid (ATC) is a lethal human malignant cancer with median
survival of 6months. To date, no treatment has substantially changed its course, which makes
urgent need for the development of novel drugs or novel formulations for drug delivery.
Nanomedicine has enormous potential to improve the accuracy of cancer therapy by
enhancing availability and stability, decreasing effective doses and reducing side effects of
drugs.
Camptothecin (CPT) is an inhibitor of DNA topoisomerase-I with several anticancer properties
but has poor solubility and a high degradation rate. Previously, we reported that CPT
encapsulated in b-cyclodextrin-nanosponges (CN-CPT) increased solubility, was protected from
degradation and inhibited the growth of prostate tumor cells both in vitro and in vivo. The aim
of this study was to extend that work by assessing the CN-CPT effectiveness on ATC both in
vitro and in vivo.
Results showed that CN-CPT significantly inhibited viability, clonogenic capacity and cell-cycle
progression of ATC cell lines showing a faster and enhanced effect compared to free CPT.
Moreover, CN-CPT inhibited tumor cell adhesion to vascular endothelial cells, migration,
secretion of pro-angiogenic factors (IL-8 and VEGF-a), expression of b-PIX, belonging to the Rho
family activators, and phosphorylation of the Erk1/2 MAPK.
Finally, CN-CPT significantly inhibited the growth, the metastatization and the vascularization of
orthotopic ATC xenografts in SCID/beige mice without apparent toxic effects in vivo. This work
extends the previous insight showing that b-cyclodextrin-nanosponges are a promising tool for
the treatment of ATC.
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Introduction
Thyroid cancers are the most common tumors of endocrine
origin and their incidence has increased globally over the past
10 years (Jemal et al., 2011). They derive from follicular and
para-follicular cells and most of them are differentiated
papillary and follicular carcinomas, while 1% of cases are
partly differentiated or undifferentiated and classified as
anaplastic thyroid carcinoma (ATC). Most differentiated
carcinomas display slow progression and are effectively
treated with thyroidectomy and radioiodine ablation
(Broecker-Preuss et al., 2015). By contrast, ATC progression
is extremely rapid and no effective systemic therapy has been
established so that the overall survival level is only 13%
(Gilliland et al., 1997). At the time of diagnosis, ATC often
display an advanced stage of development, local invasion of
the trachea, esophagus, blood vessels and muscles and
development of distant metastases to the mediastinum, lung,
liver, bone and brain (Phay & Ringel, 2013; Chen et al., 2014;
Mirrielees et al., 2014; Varinot et al., 2014). Risk factors for
thyroid cancers include environmental and genetic factors,
exposure to ionizing radiation and preexisting thyroid
neoplasia (Campanella et al., 2014). Genetic alterations
that contribute to thyroid carcinoma include point mutations
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of BRAF and RAS (Fukushima & Takenoshita, 2005;
Marotta et al., 2011); translocations involving RET/PTC1,
RET/PTC3 and PAX8/PPAR-g (Romei & Elisei, 2012;
Raman & Koenig, 2014) and alterations of the DNA
methylation pattern (Ragazzi et al., 2014; Faam et al., 2015).
To date, no effective therapies are available for ATC,
which are currently treated with trivalent therapies including
surgery, chemotherapy and radiotherapy resulting in an
increased median survival of only 5 months (Wein &
Weber, 2011; Parenti et al., 2014).
Camptothecin (CPT) is a pentacyclic alkaloid isolated from
the bark of Camptotheca acuminata, (Wall et al., 1996). It
quickly enters into cells and exerts antitumor activity by
blocking topoisomerase-1 (TOP-1) in a specific and reversible
manner. Unfortunately, it is weakly soluble in water and
undergoes spontaneous and rapid inactivation at neutral pH by
the opening of its six-member lactone E ring. Therefore, it
requires a prolonged infusion, so that the complex TOP-1 is kept
in place long enough to allow the induction of DNA damage
(Fassberg & Stella, 1992; Chourpa et al., 1998). Moreover, its
dosage and antitumor efficacy are limited by severe side effects,
such as severe myelosuppression accompanied by prolonged
diarrhea, fever, nausea and vomiting (Basili & Moro, 2009).
The main water-soluble derivatives of CPT are the irinotecan
(Compostar) and topotecan (Hycamtin).
To overcome problems in administering the drug, we
previously investigated the antineoplastic effects of CPT
loaded into nanosponges of b-cyclodextrin (CN-CPT)
(Gigliotti et al., 2016a). Results showed that CN-CPT
increased solubility was protected from degradation and
inhibited the growth of prostate tumor cells both in vitro and
in vivo to a higher extent than free CPT. Cyclodextrin
nanosponges are novel biocompatible polymer nanoparticles
obtained by cross linking of cyclodextrins (Subramanian
et al., 2012), which are cyclic oligosaccharides consisting of
multiple a-D-glucopyranose units linked together by an a-1.4
bond and include a-, b- and g-cyclodextrins carrying six,
seven or eight glucopyranose units, respectively.
b-Cyclodextrin is the most widely used for nanosponge
production because of its high capability to encapsulate drugs
(Torne et al., 2013; Trotta et al., 2014).
The aim of this study was to extend that work by assessing
the CN-CPT effectiveness on ATC both in vitro and in vivo.
Results showed that CN-CPT inhibited the growth of ATC
cell lines both in vitro and in vivo to a higher extent than free
CPT. Moreover, it inhibited tumor cell adhesion to endothelial
cells and migration which suggest that it may be effective also
to inhibit tumor metastatic dissemination.
Methods
Materials
CPT was purchased from Sigma-Aldrich (Sigma-Aldrich,
St Louis, MO). b-Cyclodextrins (b-CDs) were a gift from
Roquette (France). CD nanosponges (CNs) cross linked at 1:4
molar ratio with carbonyldiimidazole were prepared
as described previously (Swaminathan et al., 2010). All
reagents were of analytical grade. Laboratory reagents were
from Sigma-Aldrich unless otherwise specified. Cell culture
reagents were purchased from Gibco/Invitrogen (Life
Technologies, Paisley, UK) except where otherwise indicated.
Preparation of CPT in solution and camptothecin-
loaded nanosponges (CN-CPT)
To prepare the CPT solution, about 1 mg of CPT was
dissolved in 1 mL of dimethylsulfoxide (DMSO):water mix-
ture (1:1, w/w) at pH¼ 5.5. A further dilution was carried out
using 0.9% NaCl solution at pH¼ 5.5 containing 30% of
DMSO.
To load CPT in CNs, 4 mg of CPT were added to an
aqueous suspension of CNs in a ratio of 1:4 (drug to CN by
weight) at pH 5.5 and stirred for 24 h in the dark. The aqueous
suspension was then centrifuged at 8000 rpm for 10 min to
separate the free drug, not incorporated, as a solid residue
below the colloidal supernatant. The colloidal supernatant
was freeze-dried to obtain drug-loaded nanosponges as a
powder. This powder can be stored at 4 C until use.
A weighed amount of freeze-dried CN-CPT was dispersed
in a sterile aqueous solution at pH 6.0 containing 0.9% NaCl
and 3% polyethylene glycol (PEG)-400 w/v under stirring to
obtain an isotonic aqueous nanosuspension containing
100 mgmL1 of CPT for the in vivo administration. For
the free CPT formulation, a weighed amount of CPT was
dissolved in a DMSO:water mixture (1:1, w/w) at pH¼ 5.5
and then diluted with a sterile aqueous solution at pH 6.0
containing 0.9% NaCl and 3% PEG-400 w/v to obtain a
100 mgmL1 concentration. The quantitative determination of
CPT concentration in the formulations was evaluated by
HPLC (Swaminathan et al., 2010).
CN-CPT sizes and polydispersity indices were measured by
dynamic light scattering using a 90 Plus particle sizer
(Brookhaven Instruments Corporation, Holtsville, NY)
equipped with MAS OPTION (Brookhaven Instruments
Corporation, Holtsville, NY) particle sizing software. The
measurements were made at a fixed angle of 90 for all samples.
The samples were suitably diluted with filtered distilled water
for every measurement. Zeta potential measurement was then
carried out using an additional electrode in the same instrument.
For zeta potential determination, samples were diluted with
0.1 mM KCl and placed in the electrophoretic cell, where an
electric field of about 15 V/cm was applied.
The in vitro release was carried out using multicompart-
ment rotating cells with a dialysis membrane (Sartorius,
cutoff 12 000 Da). The donor phase consisted of CPT–
nanosponge formulation in phosphate buffer at pH 7.4 (1 mL).
The receiving phase consisted of phosphate buffer, pH 7.4.
The receiving phase was completely withdrawn and replaced
with fresh medium after fixed time intervals, suitably diluted
and analyzed using the HPLC method described before.
CN-CPT showed an average diameter of about 350 nm, a
polydispersity index of 0.11 and a negative surface charge
with a zeta potential value of 27.4 mV. The in vitro release
kinetics of CPT from nanosponge formulation was slow and
prolonged over time, reaching 15.5% after 24 h.
Cells
Human umbilical vein endothelial cells (HUVEC) were
isolated from human umbilical veins by collagenase treatment
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(1%) and cultured in M199 medium with the addition of 20%
fetal calf serum (FCS) 100 UImL1 penicillin, 100 mgmL1
streptomycin, 5 UImL1 heparin, 12 mgmL1 bovine brain
extract and 200 mM glutamine. HUVEC were grown to con-
fluence in flasks and used from the second to the fifth passage.
Use of HUVEC was approved by the Ethics Committee of the
‘‘Presidio Ospedaliero Martini’’ of Turin and conducted in
accordance to the Declaration of Helsinki. Written informed
consent was obtained from all donors.
The study was performed on two ATC cell lines, BHT-101
and CAL-62. Cells were purchased from Deutsche Sammlung
von Mikroorganismen and Zellculturen (Braunschweig,
Germany), which certifies the origin and identity of the
cells. The cell lines were grown in culture dishes as a
monolayer in RPMI 1640 medium plus 10% FCS, 100 UmL1
penicillin, and 100 mgmL1 streptomycin at 37 C in a 5%
CO2 humidified atmosphere (Schweppe et al., 2008).
Cell viability assay
CAL-62 and BHT-101 cells (1 103/well) were seeded in 96-
well plates and incubated at 37 C, 5% CO2, for 24 h. Then,
cells were treated with different concentrations of CN-CPT or
CPT (2 1010–2 108 M). After 24–48 h of incubation,
viable cells were evaluated by 2,3-bis[2-methoxy-4-nitro-
5sulfophenyl]-2 H-tetrazolium-5carboxanilide (MTT) inner
salt reagent at 570 nm, as described by the manufacturer’s
protocol. The controls (i.e. cells that had received no drug)
were normalized to 100%, and the readings from treated cells
were expressed as % of viability inhibition. Eight replicates
were used to determine each data point and five different
experiments were performed.
Colony-forming assay
CAL-62 and BHT-101 cells (800/well) were seeded into six-
well plates and treated with the compounds (1010–108 M).
The medium was changed after 72 h and cells were cultured
for additional 10 days. Subsequently, cells were fixed and
stained with a solution of 80% crystal violet and 20%
methanol. Colonies were then photographed and counted with
a Gel Doc equipment (Bio-Rad Laboratories, Hercules, CA).
Then, cells were washed and 30% acetic acid were added to
induce a complete dissolution of the crystal violet.
Absorbance was recorded at 595 nm by a 96-well-plate
ELISA reader. Five different experiments were performed.
Cell adhesion assay
HUVEC were grown to confluence in 24-well plates. Then,
they were pretreated with increasing concentrations of CPT or
CN-CPT (1011–108 M) for 24 h and washed twice with
fresh medium. The tumor cells (1 105 cells/well) were
seeded and left to adhere with HUVEC for 1 h, as previously
reported (Minelli et al., 2012a, 2012b). Unattached tumor
cells were washed away and the number of adherent cells was
evaluated by the Image Pro Plus Software for micro-imaging
(Media Cybernetics, version 5.0, Bethesda, MD). Viability of
the unattached cells was evaluated by the Trypan Blue test.
Data are shown as percentage of the inhibition of treated cells
versus the control adhesion measured on untreated cells; the
control adhesion was 48 ± 4 cells per microscope field (n¼ 6)
for BHT-101 cells and in a similar range (44 ± 5 cells) for
CAL-62 (mean ± SEM) (Dianzani et al., 2010).
Cell motility assay
In the wound-healing assay, after starvation for 18–24 h in
serum-free medium, cells were plated onto six-well plates
(106 cell/well) and grown to confluence. Cell monolayers
were wounded by scratching with a pipette tip along the
diameter of the well, and they were washed twice with serum-
free medium before their incubation with culture medium in
the absence or presence of CPT or CN-CPT (108 M) and
mitomycin C (50 mgmL1, Sigma-Aldrich, St Louis, MO). In
order to monitor cell movement into the wounded area, five
fields of each wound were photographed immediately after
the scratch (0 h) and after 24 h (Dianzani et al., 2014; Gigliotti
et al., 2016a).
In the Boyden chamber (BD Biosciences, San Jose, CA)
invasion assay, cells (8000) were plated onto the apical side of
50 mgmL1 Matrigel-coated filters (8.2 mm diameter and
0.5 mm pore size; Neuro Probe, Inc.; BIOMAP snc, Milan,
Italy) in serum-free medium with or without increasing
concentration of the drugs (2 109–2 108 M). Medium
containing 20% FCS was placed in the basolateral chamber as
a chemo attractant. After 24 h, cells on the apical side were
wiped off with Q-tips. Cells on the bottom of the filter were
stained with crystal violet and counted (five fields of each
triplicate filter) with an inverted microscope. Data are shown
as percentages of the inhibition of treated cells versus the
control migration measured on untreated cells. Control
migration was 52 ± 4 cells per microscope field (n¼ 5) for
BHT-101 cells and 66 ± 5 for CAL-62 (Occhipinti et al.,
2013).
ELISA assay
CAL-62 or BHT-101 cells (1 105/well) were plated in 24-
well plates and treated with CPT or CN-CPT (1011–108 M)
for 48 h. CPT and CN-CPT were replenished every 24 h (48 h
culture: 24 + 24 h) without changing the culture medium.
Cell-free supernatants were collected and concentrations of
Interleukin-8 (IL-8), vascular endothelial growth factor a
(VEGF-a) and angiopoietin 2 were measured by ELISA
according to the instructions of the manufacturers (IL-8,
eBioscience, SanDiego, CA; VEGF-a and angiopoietin 2,
R&D Systems, Minneapolis, MN). Absorbance was detected
with a microplate reader (Bio-Rad Laboratories, Hercules,
CA), and the Excel program was used to calculate the
standard curve.
Protein extraction and western blot analysis
Cells were seeded into six-well plates and treated for 48 h with
CPT or CN-CPT (108–109 M). CPT and CN-CPT were
replenished every 24 h (48 h culture: 24 + 24 h) without
changing the culture medium. Cells were then lysed in a
buffer composed of 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
5 mM EDTA, 1% sodium deoxycholate, 1% Nonidet P-40,
0.1% SDS, phosphatase and protease inhibitor cocktail. Cell
lysates were cleared from insoluble fractions by high-speed
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centrifugation, and protein concentration was determined with
a commercially available kit (Bio Rad Laboratories, Hercules,
CA) and measured with a spectrophotometer (Jasco Analytical
Instruments, Easton, MD). Proteins (40 mg) were loaded on
10% SDS-PAGE gels and transferred onto nitrocellulose
membranes after electrophoresis. These were blocked by
incubation for 1 h at room temperature with 5% nonfat milk
dissolved in TBS-Tween 20. The membranes were then probed
overnight with antibodies to b-PIX (AdipoGen International,
San Diego, CA), pospho-Erk1,2 (Santa Cruz Biotechnology,
Dallas, TX), or b-actin (Sigma-Aldrich, St Louis, MO) and,
after three washes, incubated for 1 h with the HRP-conjugated
secondary antibody antibody antibody (Sigma-Aldrich, St
Louis, MO). Bands were detected by chemiluminescence, and
densitometric analysis was performed with the Multi-Analyst
software (version 1.1, Bio-Rad Laboratories, Hercules, CA).
Cell-cycle analysis
Cells (1.5 105) were treated with CPT or CN-CPT as
reported earlier. After 48 h, adherent and nonadherent cells
were collected, washed in PBS and fixed in 75% ice-cold
ethanol and subsequently resuspended in a buffer containing
0.02 mgmL1 RNase A (Worthington Biochemical
Corporation, Lakewood, NJ), 0.05 mgmL1 propidium
iodide (BD Biosciences, San Jose, CA), 0.2% v/v Nonidet
P-40, 0.1% w/v sodium citrate. Samples were analyzed with a
FACSCalibur cytometer (BD Biosciences, San Jose, CA).
Annexin V staining and caspase-3 activity
Cells (1.5 105) were treated with CPT or CN-CPT as
reported earlier. After 48 h, they were stained with annexin V
using the Annexin V Fluos kit (BD Biosciences, San Jose,
CA) and analyzed by flow cytometry. Live cells were those
not displaying shrunken/hypergranular morphology and
unstained by AnnexinV. Caspase-3 activity was assessed in
cell lysates using a fluorimetric assay (MBL, Watertown,
MA) following the manufacturer instructions.
In vivo animal models and tumor growth
Animal studies were performed in accordance with EU and
institutional guidelines approved by the Bioethics Committee
for Animal Experimentation of the University of Turin, Italy
(Prot. No. 4.2/2012) using NOD-SCID IL2Rgnull (NSG; 10/
11-week-old female) mice, bred under sterile conditions in
our animal facilities. Animals were anesthetized with intra-
muscular injection of Zoletil (Zolaxepan and Tiletamina)
and Rompun (Xylazina). CAL-62 cells were harvested from
subconfluent cultures by trypsinization and washed in PBS.
Then, cells (106 cells in 10 mL) were injected into the right
thyroid lobe under surgical sterile conditions and tumors were
allowed to grow during the following 10 days. Mice were then
randomized into three groups receiving twice weekly intra-
venous injection of PBS (control group, n¼ 5) or 1 mgkg1
CPT (n¼ 7) or 1 mgkg1 CN-CPT (n¼ 7).
Mice were weighed twice weekly and sacrificed when the
animals appeared moribund. Tumor growth velocity (Tv) was
determined using the formula: Tv¼V/days from cells injec-
tion to excision.
Tumors and lungs were fixed in 10% formalin and paraffin
embedded. Four serial sections/tumor were obtained and
processed for immunohistochemistry using an automated
slide processing platform (Ventana BenchMark XT
AutoStainer, Roche) and a mouse monoclonal anti-human
Ki-67 (Clone MIB-1) or a rabbit polyclonal anti-mouse CD31
(Abcam, Cambridge, UK) antibodies. Sections of lungs were
stained with hematoxylin and eosin (H&E).
Ki-67-positive cells were heterogeneously distributed
throughout the tumor. The Ki67-labeled nuclei were
evaluated in the tumor areas where these markers were
predominant (hot spots) using a digital camera (Olympus
Q-colour 3, Tokyo, Japan) with area-based image analysis
software (Dot-Slide 1.2 version, Tokyo, Japan). Ki-67
expression was calculated as the ratio between the labeled
and the total nuclear areas. Only nuclei with a strongly
positive label were counted. The 10 fields with the highest
density of positive nuclei were captured. A mean of 3000
tumor cells per case (range 2000–3800) was counted.
Tumor microvessel density (TMD) was measured by
evaluating the CD31-positive area and total tumor area
per field upon slide after scan (Panoramic midi II, 3 D
Histech, Budapest, Hungary) of the immunostaining, as
previously described (Gigliotti et al., 2016a; Passaro et al.,
2016).
Data analysis
Data are shown as mean ± standard error of the mean (SEM).
Statistical analyses were performed with GraphPad Prism 5.0
software (San Diego, CA). For the in vivo experiments,
the results are expressed as the median with interquartile
range. One-way ANOVA was performed, followed by
Tukey’s multiple comparison post-test when needed.
Kaplan–Meier survival curves were evaluated with the log
rank Mantel-Cox test. Only p values50.05 were considered
to be significant.
Results
CN-CPT inhibits cell proliferation in vitro
We compared the ability of CN-CPT and free CPT to inhibit
the growth of BHT-101 and CAL-62 in vitro. Cells were
cultured in the presence and absence of titrated amounts
(2 1010–2 108 M) of each compound for 24–48 h and
the amount of viable cells was then assessed by the MTT
assay. Figure 1 shows that CN-CPT inhibited the growth of
both cell lines to a higher extent than CPT. The effect was
concentration- and time-dependent with small differences
between the two cell lines. The different effect of the two
compounds was detectable in terms of timing, maximal
inhibition, and effective doses.
To validate these findings, we performed clonogenic
survival assays. Cells were seeded onto six-well plates and
treated with titrated doses (1010–108) of each compound.
The culture medium was changed after 72 h, and cells were
cultured for 10 additional days in the absence of the
compounds. Results showed that treatment with CN-CPT
inhibited the ability to form colonies of both cell lines to a
higher extent than CPT (supporting information, Figure S1).
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The effect was concentration dependent with small differ-
ences between the two cell lines. The different effect of the
two compounds was detectable in terms of effective doses
but not in terms of maximal inhibition that was similar at the
highest dose.
To assess whether inhibition of cell proliferation induced
by CN-CPT-affected cell-cycle progression, we analyzed the
cell cycle in CAL-62 and BHT-101 cells cultured in the
presence and absence of titrated amounts of CN-CPT or CPT
(109 and 108 M) for 48 h. Results showed that both doses of
CN-CPT induced a substantial accumulation of cells in S
phase compared to the untreated control in both cell lines.
This effect was exerted also by CPT but only at the highest
dose (Figure 2).
To assess whether inhibition of cell proliferation induced
by CN-CPT involved cell death, we analyzed Annexin V
staining, detecting both apoptotic and necrotic cells, and
caspase 3 activation, detecting apoptosis, in CAL-62 and
BHT-101 cells cultured in the presence and absence of titrated
amounts (109 and 108 M) of CN-CPT or CPT for 48 h.
Results showed that CN-CPT induced higher Annexin V
staining and caspase 3 activation than CPT in both cells lines
(Figure 3).
CN-CPT inhibits cell adhesion and migration in vitro
Adhesion of tumor cells to the vascular endothelium and their
release into the bloodstream is a key step for metastasis
formation (Ma & Waxman, 2008). Therefore, we performed
in vitro experiments comparing the effect of CN-CPT and
CPT on adhesion to HUVEC and motility of tumor cells.
In the adhesion experiments, HUVEC were pretreated for
24 h with titrated doses (1011 and 108 M) of CN-CPT and
CPT, washed, and used for adhesion assays with CAL-62 and
BHT-101 cells. Results showed that CN-CPT inhibited
adhesion of both cell lines at higher levels than CPT. The
effect was concentration dependent with small differences
between the two cell lines. The different effect of the two
compounds was detectable in terms of both effective doses
and maximal inhibition (Figure 4A–B). The difference was
not due to an effect on cell viability since cells were still alive
after the 24-h incubation with the drug.
Cell motility was initially assessed using a wound healing
assay evaluating cell random migration. A linear scratch was
done in confluent monolayers of CAL-62 and BHT-101 cells,
which were then cultured in FCS-free medium to minimize
cell proliferation in the presence or absence of CN-CPT and
CPT (108 M). Analysis of the cell ability to migrate into the
Figure 1. Inhibition of cell viability following CPT or CN-CPT treatments. CAL-62 (A, B) or BHT-101 (C,D) cells (1 103/well) were treated with the
indicated concentrations of drug for 24–48 h. Results are expressed as % of viability inhibition of control and shown as mean ± SEM (n¼ 5). *p50.05,
**p50.01 significantly different from the same concentration of CPT.
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scratch after 24 h showed that CN-CPT inhibited adhesion of
both cell lines at higher levels than CPT (supporting
information, Figure S2). Then, cell motility was assessed
using a Boyden chamber assay assessing directional migration
of cells. CAL-62 and BHT-101 cells were seeded in the upper
chamber of a Boyden chamber in serum-free medium in the
presence or absence of titrated doses (2 109 and
2 108 M) of CN-CPT and CPT and allowed to migrate
for 24 h toward the lower chamber containing medium with
and without 20% FCS, used as a chemoattractant. Results
showed that CN-CPT inhibited cell migration at higher levels
than CPT in both cell lines (Figure 4C–D). The CN-CPT
effect was concentration dependent with small differences
between the two cell lines, whereas CPT displayed some
effect on CAL-62 cells but it was almost ineffective on BHT-
101 cells.
In both migration assays, doses and timing of treatments
minimized the possible confounding effects due to the drug
effect on cell growth.
CN-CPT inhibits VEGF-a and IL-8 secretion in vitro
Since ATC cells express high levels of pro-angiogenic
molecules (Jayasooriya et al., 2011; Passaro et al., 2016),
we evaluated the effect of the drugs on secretion of VEGF-a,
IL-8 and angiopoietin 2. CAL-62 and BHT-101 cells were
incubated with titrated doses (1011–108 M) of CN-CPT or
CPT for 48 h. Then, secretion of VEGF-a, IL-8 and
angiopoietin 2 was evaluated by ELISA in the culture
supernatants. Results showed that the ATC cells produced a
substantial amount of these factors and CN-CPT inhibited the
secretion of VEGF-a and IL-8 compared to the free drug at
the same concentrations (supporting information, Figure S3).
No differences were found for angiopoietin 2 secretion (data
not shown).
CN-CPT inhibits b-PIX expression and ERK1,2
phosphorylation in vitro
In order to investigate the mechanisms underlying CN-CPT-
mediated inhibition of cell proliferation, adhesion and
migration, we evaluated the effect of the drug on expression
of b-PIX, involved in rearrangement of the cytoskeleton and
cell migration and on Erk1,2 phosphorylation involved in
signaling of multiple surface receptors (Kim et al., 2013;
Occhipinti et al., 2013; Dianzani et al., 2014; Stevens et al.,
2014; Gigliotti et al., 2016b). CAL-62 and BHT-101 cells
were incubated with titrated doses (109 and 108 M) of CN-
Figure 2. Induction of cell-cycle arrest by CPT or CN-CPT treatment. CAL-62 (A, B) and BHT-101 (C, D) cells (1.5 105) were treated or not with
CPT or CN-CPT (108 and 109 M) for 48 h and cell cycle was then assessed by flow cytometry. CPT and CN-CPT were replenished every 24 h (48 h
culture: 24 + 24 h) without changing the culture medium. Graphs show: (A, C) the % of cells in each cycle phase detected in one representative
experiment, (B, D) the % of cells in S phase cycle expressed as means ± SEM (n¼ 3). Each experiment was performed in triplicate. xxp50.01,
significantly different from untreated cells; *p50.05, **p50.01, significantly different from treated cells at the same drug concentration.
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CPT or CPT for 48 h, lysed and analyzed for b-PIX expression
and Erk1,2 phosphorylation by Western blot. Results showed
that CN-CPT inhibited b-PIX expression and Erk1,2 phos-
phorylation at higher levels than CPT in both cell lines
(Figure 5).
In vivo studies
We compared the effect of CN-CPT and CPT tumor growth
and metastatic dissemination in NSG mice injected orthoto-
pically in the thyroid lobe with CAL-62 cells and treated
10 days later with twice weekly injections of PBS, CPT or
CN-CPT in the tail vein. Results showed that the overall
survival of mice treated with CN-CPT was higher than that
displayed by mice injected with either PBS or CPT (Figure
6A). In particular, median survivals of mice treated with PBS,
CPT and CN-CPT were 28, 25 and 38 days, respectively. The
difference of survival between the CN-CPT group and the
control group was significant (p¼ 0.0422, log-rank test).
Analysis of tumor growth velocity showed that CN-CPT
significantly inhibited the growth velocity of orthotopic
anaplastic thyroid carcinoma xenografts compared to the
control group, whereas CPT had no effect (Figure 6B).
Analysis of lung metastases showed that CN-CPT signifi-
cantly inhibited development metastases compared to the
control group, whereas CPT had no effect (Figure 6C).
Histologic analysis of the primary tumor showed that, in
control mice, the tumors displayed diffuse necrosis whereas,
in CN-CPT-treated mice, tumors displayed decreased necro-
sis, and in CPT-treated mice an intermediate picture.
Immunohistochemical staining, performed 34 days after
tumor challenge showed that Ki-67+ cells were homoge-
neously distributed in the tumor mass in PBS- and CPT-
treated mice, whereas, they were concentrated at the invasive
edge in the peripheral area of the tumor, but rare in the center
of the tumor, in CN-CPT-treated mice (Figure 6D). This
enrichment of Ki67+ cells was detected also at 51 days after
tumor challenge (Figure 6E). To assess the effects on tumor
angiogenesis, we stained the tumor sections for CD31 and
evaluated the TMD. Results showed that treatment with
CN-CPT substantially decreased the TMD compared with
untreated mice and CPT-treated mice, whereas CPT had no
effect (Figure 6F).
All treatments were well tolerated by the animals without
significant weight loss in any group.
Figure 3. Proportions of Annexin-V-positive cells and levels of caspase-3 activity after CPT or CN-CPT treatment. Annexin-V-positive cells (A, B) and
caspase-3 activity (C, D) was evaluated in CAL-62 (A, C) and BHT-101 (B, D) cells cultured for 48 h in the presence or absence of CPT or CN-CPT.
CPT and CN-CPT were replenished every 24 h (48 h culture: 24 + 24 h) without changing the culture medium. Results are expressed as % of Annexin-V-
positive cells and relative caspase activity %, calculated as result displayed by each treatment/the results displayed by untreated cells (n¼ 5). xp50.05;
xxp50.01, significantly different from untreated cells; *p50.05; **p50.01, significantly different from treated cells at the same drug concentration.
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Discussion
ATC is a highly aggressive tumor with a poor prognosis and
the long-term survival is extremely rare. To date, available
therapies do not significantly improve the survival of patients
and have only a palliative effect (Patel & Shaha, 2006;
Cornett et al., 2007).
CPT belongs to the drug category of inhibitors of DNA
TOP-1 by specifically blocking TOP-1 during the cleavage
reaction of DNA and preventing repair of the single-strand
breaks. This effect produces blocking of cells in the S phase
of the cell cycle, conversion of DNA breaks from single to
double helix and death of cells by apoptosis (Huang et al.,
2000; Desai et al., 2001; Minelli et al., 2012a). Several studies
demonstrated CPT activity in tumors of various origins, but
CPT did not reach clinical use because of its numerous side
effects. Moreover, its use is restricted by poor solubility and
stability at physiological pH, at which CPT undergoes
spontaneous inactivation due to opening of the E ring,
decreased bioavailability and enhanced side effects. Several
strategies have been described to improve the CPT activity
and to decrease the side effects in several type of cancers
(Acevedo-Morantes et al., 2013; Xie et al., 2016; Yang et al.,
2016).
Previously, we have reported that CN-CPT displays
increased solubility, is protected from degradation and
displays an enhanced inhibitory effect on prostate tumor
cells both in vitro and in vivo (Fassberg & Stella, 1992;
Chourpa et al., 1998; Minelli et al., 2012a, 2012b; Gigliotti
et al., 2016a).
This work extends those observations to ATC showing that
CN-CPT displays increased inhibitory effects in vitro on cell
proliferation, as assessed by the MTT and clonogenic assay
and increased ability to block the cell cycle into the S phase
and to induce apoptosis. These effects may be ascribable to
the inhibitory activity of CPT on TOP-1. Moreover, a role
may be played also by inhibition of Erk 1,2 phosphorylation
since constitutive activation of MAPK signaling is involved in
cell survival and proliferation in several cancers, including
thyroid cancer (Lim & Cha, 2011; Perri et al., 2015). It is
noteworthy that inhibitors of the MAPK pathway may
increase the efficacy of radioiodine therapy in cancer with
BRAF mutations (Knauf et al., 2009).
Figure 4. Effect of CPT and CN-CPT on cells adhesion and cell migration of CAL-62 and BHT-101 cell lines. (A,B) HUVEC were treated or not
treated with CPT or CN-CPT for 24 h, washed and used in the adhesion assay with untreated CAL-62 (A) and BHT-101 (B) cells (1 105/well). The
data are presented as percentage of inhibition of the adhesion of treated cells compared to control (untreated cells). Each experiment was performed in
triplicate. Data shown are means ± SEM (n¼ 5). *p50.05; **p50.01 significantly different from the same concentration of CPT. (C,D) In the Boyden
chamber assay, CAL-62 (C) and BHT-101 (D) cells were plated onto the apical side of Matrigel-coated filters in the presence and absence of either CPT
or CN-CPT, and FCS 20% was loaded in the basolateral chamber as a chemotactic stimulus. Data are expressed as mean ± SEM (n¼ 5) of the
percentage of inhibition versus control migration **p50.01 significantly different from the same concentrations of CPT.
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The in vitro experiments demonstrated that CN-CPT also
shows increased ability to inhibit endothelial cells adhesive-
ness to ATC cells and migration of ATC cells, similarly to
what we previously showed for prostate cancer cells. This
activity might be related to the ability of CN-CPT to
downmodulate expression of b-Pix involved in negative
regulation of formation of focal adhesions, which may
enhance formation of lamellipodia and cell motility (Kim
et al., 2013; Occhipinti et al., 2013; Dianzani et al., 2014;
Stevens et al., 2014).
The in vivo experiments using the SCID xenograft
orthotopic model implanted with CAL-62 cells substantially
supported these findings since treatment with CN-CPT
was more effective than the free drug in improving mice
survival and decreasing tumor growth and metastatization at a
dose (1 mgkg1) that did not display any substantial side
effects.
Beside the effect on cell proliferation, apoptosis, adhesion
and migration, the antitumor CN-CPT activity may also
involve inhibition of tumor neoangiogenesis as suggested by
the CN-CTP ability to inhibit VEGF-a and IL-8 secretion in
ATC cells lines in vitro and tumor vascularization in vivo. We
previously showed that CN-CPT, but not free CPT, inhibits
proliferation and migration of endothelial cells, proteolytic
degradation of the extracellular matrix, and in several in vitro
models of angiogenesis, inhibited tumor neoangiogenesis in
mouse models of prostate cancer (Gigliotti et al., 2016a).
Solid tumors cannot grow beyond a certain size, generally
1–2 mm3, without being supported by tumor neoangiogenesis
(Li et al., 2012), that plays a key role also for metastatic
dissemination of cancer cells. Another point is that the higher
in vivo activity of CN-CPT compared to free CPT may be
partly due to its ability, displayed by most nanoparticles, to
accumulate in tumors because of the enhanced permeation
and retention effect across the atypical highly fenestrated
blood vessels of the tumor (Wang & Thanou, 2010).
The greater size of the necrotic core detected in the tumors
of the control group compared to those of the CN-CPT-treated
group may be ascribed to the faster growth of the former that
may prevent adequate nutrition of the tumor core. The finding
that the tumors of CN-CPT-treated mice contained a high
density of Ki67+ cells at the invasive edge suggests that the
antiproliferative activity of the drug has limited effects in this
area of the tumor. However, the CN-CPT effect might be
potentiated by combination of CN-CPT with surgery and
radiation, since the multimodality approach represents the
standard treatment of choice in ATC (Denaro et al., 2013) and
the striking CN-CPT effect on tumor metastatization may be
crucial to implement the effect of those therapies. The safety
(Gigliotti et al., 2016a) and the cheap cost of CN-CPT are also
to be considered.
Conclusions
In conclusion, the antineoplastic activity of CN-CPT may
result from the combination of the antiproliferative effect
Figure 5. Effect of CPT and CN-CPT on b-PIX expression and Erk1,2 phosphorylation in CAL -62 (A), and BHT-101 (C). Cells were treated with CPT
or CN-CPT (108 and 109 M) for 48 h. CPT and CN-CPT were replenished every 24 h (48 h culture: 24 + 24 h) without changing the culture medium.
The same blots were probed with anti b-actin antibody as a control. (A, C): Western blot analysis from a representative experiment. (B, D):
Densitometric analysis of b-PIX expression and Erk1,2 phosphorylation expressed in arbitrary units; data are expressed as means ± SEM (n¼ 3) and
shown as % of the controls. xp50.05 significantly different from untreated cells; *p50.05 significantly different from treated cells at the same
concentration.
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associated with the increase in apoptosis in the tumor cells,
the inhibition of migration, invasion and metastatization, and
the inhibition of the neoplastic neovascularization. Therefore,
the anticancer activity of CN-CPT, without evident toxicity,
opens up therapeutic perspectives for the ATC, which does
not respond to conventional therapy. Translational and
clinical studies will ultimately determine the clinical utility
and safety of CN-CPT, used alone or in combination with
other chemotherapics, as an option for the treatment of this
kind of tumor.
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